Loading stock data…
$543.42+0.02 (+0.00%)
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
United Therapeutics Corporation in the Healthcare sector is trading at $543.42 with a market capitalization of $23.4B. Wall Street consensus targets $651.15 (13 analysts), implying a +19.8% move over the next 12 months. The stock is currently 11% below its 52-week high of $609.35, remaining 3.2% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | $798.60M↓ | $799.50M↑ | $790.20M↑ | $781.50M↓ | $783.30M |
| Gross Profit | $711.00M↑ | $698.60M↑ | $686.80M↑ | $648.10M↓ | $683.80M |
| Operating Income | $386.20M↓ | $389.30M↑ | $357.50M↑ | $325.80M↓ | $330.80M |
| Net Income | $309.50M↓ | $338.70M↓ | $364.30M↑ | $274.90M↓ | $333.00M |
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an ...